The CHLSN Knockout HAP1 Polyclonal Cells are a genetically engineered polyclonal population derived from HAP1 cells, generated by CRISPR/Cas9-mediated disruption of the CHLSN gene. As a polyclonal knockout pool, this product provides a heterogeneous mixture of edited cells, avoiding clonal artifacts and enabling robust loss-of-function studies. The targeted disruption abolishes expression of the CHLSN adhesion molecule, offering a valuable tool for population-level investigations such as pooled genetic screens and biochemical assays requiring sufficient biomass.
The host cell line, HAP1, is a human near-haploid fibroblast-like line originally derived from the chronic myeloid leukemia-derived hematopoietic progenitor cell line KBM-7. HAP1 cells are haploid for the majority of chromosomes, with the exception of an approximately 30 Mb diploid region on chromosome 15, which simplifies genetic analysis and enables straightforward interpretation of knockout phenotypes. Their adherent, fibroblast-like morphology and robust proliferation make them an experimentally tractable system for cell adhesion, migration, and signaling studies. The hematopoietic progenitor origin further allows examination of how neuronal adhesion molecules might influence processes in non-neuronal contexts.
CHLSN encodes a transmembrane cell adhesion molecule that mediates homophilic cell-cell interactions and promotes neurite outgrowth through heterophilic engagement with partners including L1CAM, NCAM1, and integrin heterodimers such as ITGA5/ITGB1. Upon ligand binding, CHLSN nucleates a signaling complex that recruits and activates FGFR1, leading to downstream phosphorylation of MAPK1 (ERK2) and AKT1 via the GRB2-ERK1/2 and PI3K axes. These pathways converge on transcription factors like CREB1 to regulate synaptic plasticity and axonal guidance. Upstream, CHLSN expression is modulated by NOTCH1, BDNF, and NGF, integrating neurotrophic cues. Knockout of CHLSN uncouples extracellular signals from intracellular effectors, providing a clean loss-of-function system.
Given CHLSN’s genetic associations with neurodevelopmental disorders such as schizophrenia, autism spectrum disorder, and 3p26 microdeletion syndrome, this haploid HAP1 knockout model serves as a reductionist platform to dissect basic biochemical and cell biological defects underlying these conditions. The haploid background enhances detection of subtle phenotypes, including alterations in cell adhesion kinetics, migration speed, and integrin activation, which might otherwise be masked by diploid redundancy. Moreover, complementation with exogenous disease-associated variants or interacting partners enables detailed structure-function analyses and drug response profiling.
This CHLSN knockout polyclonal cell pool is suitable for a wide range of experimental approaches, including Western blotting and RT-qPCR for expression validation, flow cytometry and immunofluorescence to assess surface receptor levels, and cell adhesion or migration/invasion assays to evaluate functional outcomes. Co-immunoprecipitation experiments can map disrupted protein-protein interactions, while pooled CRISPR screens can employ this line as a baseline for identifying synthetic lethal or modifier interactions. It equally supports drug target validation by assessing the dependency of small-molecule inhibitors on intact CHLSN signaling. For additional details or custom requirements, please contact Ascent Research.
